<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-52226" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hematopoietic Stem Cell Transplantation in Sickle Cell Disease</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashorobi</surname>
            <given-names>Damilola</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Naha</surname>
            <given-names>Kushal</given-names>
          </name>
          <aff>University of Missouri-Columbia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatt</surname>
            <given-names>Ruchi</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Damilola Ashorobi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kushal Naha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ruchi Bhatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-52226.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Since the Sickle Cell Anemia Act, steady progress has been made in the screening and treatment of sickle cell disease. Despite the development of new medical therapies, sickle cell disease remains an incurable condition for most affected individuals.&#x000a0;Hematopoietic stem cell transplantation represents the only currently available curative option for&#x000a0;individuals living with sickle cell disease. Hematopoietic stem cell&#x000a0;transplantation may be autologous, requiring genetic modification of the patient's stem cells to correct the genetic mutation characteristic of sickle cell disease, or allogeneic, involving replacement of the defective stem cells with healthy stem cells from a suitable donor. Although HSCT is curative for most patients, the procedure is associated with significant toxicities and occasionally fatal complications. Care must be exercised when selecting patients for HSCT. This activity reviews the therapeutic role of HSCT in sickle cell disease and highlights the role of the interprofessional team in&#x000a0;caring for patients who undergo the procedure.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with sickle cell disease who may be candidates for hematopoietic stem cell transplantation based on their clinical history.</p></list-item><list-item><p>Assess and manage the complications of hematopoietic stem cell transplantation in sickle cell disease.</p></list-item><list-item><p>Effectively counsel patients with sickle cell disease and their caregivers about the risks and benefits of hematopoietic stem cell transplantation.</p></list-item><list-item><p>Develop and implement interprofessional team strategies to improve outcomes for patients with sickle cell disease undergoing hematopoietic stem cell transplantation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=52226&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=52226">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-52226.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sickle cell disease (SCD) is the most common hemoglobinopathy in the United States. SCD affects about 100,000 Americans, mostly of African descent.<xref ref-type="bibr" rid="article-52226.r1">[1]</xref>&#x000a0;Approximately 20 million individuals worldwide are affected by SCD. The molecular basis of SCD was poorly understood when the disease was first described in the early 1900s. It was not until 1949 when Dr. Linus Pauling carried out a landmark study, that it was determined that&#x000a0;this condition&#x000a0;is caused by abnormal hemoglobin that sickles&#x000a0;when exposed to a low-oxygen environment. The abnormal form of hemoglobin in&#x000a0;SCD arises from a single amino acid mutation in the beta-globin gene called hemoglobin S.<xref ref-type="bibr" rid="article-52226.r2">[2]</xref></p>
        <p>Because&#x000a0;SCD is an autosomal recessive disorder,&#x000a0;both beta-globin genes must be mutated&#x000a0;for an individual to develop overt disease. When only a single copy of the gene is mutated, the resulting phenotype is termed&#x000a0;sickle cell trait. Sickle cell trait is usually benign, but&#x000a0;affected persons may&#x000a0;develop sickled cells when exposed to&#x000a0;exceptionally low pressures of oxygen.</p>
        <p>Since 1949, scientists have made steady progress in understanding the complex molecular pathology of SCD. However, until about two decades ago, no known cure for this genetic disorder existed. According to Dr. Mary T. Basset, a physician during the American civil rights movement,&#x000a0;SCD research, screening, and treatment received little to no funding and was neglected because patients were primarily of African descent.<xref ref-type="bibr" rid="article-52226.r3">[3]</xref>&#x000a0;One of the significant achievements of the civil rights movement in the 1970s was the establishment of&#x000a0;the Sickle Cell Disease Association of America&#x000a0;and the&#x000a0;creation of the Sickle Cell Anemia Act of 1972. Since then, there has been&#x000a0;greater&#x000a0;public awareness of&#x000a0;SCD and incrementally more funding towards finding a cure, culminating in the first bone marrow stem cell transplant for SCD.&#x000a0;</p>
        <p>The Sickle Cell Anemia Act also improved screening processes for SCD. Today, in most parts of the United States, sickle cell screening is&#x000a0;performed before discharging&#x000a0;neonates from the hospital. This screening allows for early medical intervention&#x000a0;and reduces morbidity and mortality from SCD. Treatment of&#x000a0;SCD has improved,&#x000a0;incorporating penicillin prophylaxis for children younger than 5, hydroxyurea&#x000a0;to boost fetal hemoglobin levels, prophylactic blood transfusions, and pain medications, including opioids. Unfortunately, most of these treatments are palliative, and patients&#x000a0;continue to experience&#x000a0;poor quality of life because of&#x000a0;recurrent pain episodes, end-organ damage, and a reduced life expectancy, underscoring the importance of seeking a cure for this condition.</p>
        <p>In September 2018, the National Heart, Lung, and Blood Institute (NHLBI) launched the Cure Sickle Cell Initiative. Under this initiative, efforts are being made to develop new genetic approaches to cure SCD.<xref ref-type="bibr" rid="article-52226.r4">[4]</xref><xref ref-type="bibr" rid="article-52226.r5">[5]</xref>&#x000a0;Advancement in gene therapy techniques has shown promising results in preclinical and clinical trials, but formal approval by the United States Food and Drug Administration (FDA) is still awaited.<xref ref-type="bibr" rid="article-52226.r2">[2]</xref><xref ref-type="bibr" rid="article-52226.r3">[3]</xref><xref ref-type="bibr" rid="article-52226.r6">[6]</xref><xref ref-type="bibr" rid="article-52226.r7">[7]</xref></p>
      </sec>
      <sec id="article-52226.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>Sickle cell disease is a genetic disorder inherited in an autosomal recessive manner.&#x000a0;The hallmark mutation&#x000a0;of SCD affects the sixth amino acid in the hemoglobin beta-chain, replacing the normal glutamate residue with valine. This point mutation results in hemoglobin polymerization in a hypoxic environment leading to&#x000a0;the deformation of red blood cells and occlusion of the microvasculature.&#x000a0;The resulting organ ischemia produces multiple organ damage typical of sickle cell disease.<xref ref-type="bibr" rid="article-52226.r2">[2]</xref></p>
      </sec>
      <sec id="article-52226.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Although hematopoietic stem cell transplantation (HSCT) remains the only available curative therapy for SCD, not all&#x000a0;affected individuals are eligible for&#x000a0;such therapy, primarily because of the significant toxicities associated with the procedure.&#x000a0;HSCT is currently indicated in persons with severe&#x000a0;SCD with complications including stroke, acute chest syndrome, recurrent pain crisis, nephropathy, retinopathy, osteonecrosis of multiple joints, and priapism.<xref ref-type="bibr" rid="article-52226.r6">[6]</xref>&#x000a0;The decision to proceed with&#x000a0;HSCT is complex and must include a discussion of potential benefits and risks, such as infection, graft-versus-host disease (GVHD), and organ injury from the conditioning regimen. In addition, HSCT can have unpredictable effects on preexisting heart, lung, and kidney diseases. Transplantation is only&#x000a0;indicated when the benefits outweigh these risks.<xref ref-type="bibr" rid="article-52226.r8">[8]</xref><xref ref-type="bibr" rid="article-52226.r9">[9]</xref><xref ref-type="bibr" rid="article-52226.r10">[10]</xref></p>
        <p>HSCT should ideally be performed in children with SCD at high risk for severe disease before the onset of complications. Unfortunately, without effective and validated biomarkers, predicting when such individuals might develop complications is challenging. The development of effective medical therapies has also complicated decisions&#x000a0;regarding HSCT, as there are no prospective head-to-head comparisons of these&#x000a0;medical therapies against HSCT. Thus, HSCT is more likely to benefit individuals who do not wish to utilize chronic medical therapy. The uncertainty around HSCT in SCD is reflected in the 2014 guidelines issued by the NHLBI, acknowledging that additional research was required for patient and donor selection and to determine the optimal transplantation&#x000a0;regimen before HSCT could be made widely available as a curative procedure for SCD.<xref ref-type="bibr" rid="article-52226.r11">[11]</xref></p>
        <p>It is generally agreed that HSCT is indicated in children with progressive organ dysfunction, such as worsening cardiac, renal, and pulmonary function, recurrent stroke, and recurrent priapism, despite the institution of optimal medical therapy. HSCT can also be considered in older adolescents and young adults who can make an informed decision regarding the risks and benefits of the procedure. Regardless of the patient's age, the availability of a suitable donor, such as a fully matched sibling, is an essential requirement.<xref ref-type="bibr" rid="article-52226.r12">[12]</xref>&#x000a0;Alternate donors, such as haploidentical and matched unrelated donors, may be considered in selected cases.<xref ref-type="bibr" rid="article-52226.r13">[13]</xref></p>
        <p>The optimal age for receiving HSCT has not been established. However, several retrospective studies have shown improved survival after HSCT in children compared to adults, especially in children below the age of 10.<xref ref-type="bibr" rid="article-52226.r14">[14]</xref><xref ref-type="bibr" rid="article-52226.r15">[15]</xref>&#x000a0;Similarly, the optimal source of donor stem cells is unclear. Donor stem cells can be derived from umbilical cord blood, bone marrow, or mobilized peripheral blood. Of these sources, umbilical cord blood and bone marrow are expected to have the best outcomes; stem cells from these sites are associated with a lower risk of GVHD than peripheral blood. However, at least one study of HSCT in SCD did not show a lower incidence of GVHD with cord blood and bone marrow stem cells, although overall survival was&#x000a0;superior with these sources compared to peripheral blood stem cells.<xref ref-type="bibr" rid="article-52226.r15">[15]</xref></p>
      </sec>
      <sec id="article-52226.s5" sec-type="Preparation">
        <title>Preparation</title>
        <p>Hematopoietic stem cell transplantation is a complicated process involving multiple&#x000a0;tests and extensive preparation. Routine laboratory testing must be performed, including a complete blood count, comprehensive metabolic profile, and 24-hour urine protein and creatinine. Brain&#x000a0;magnetic resonance imaging and magnetic resonance angiography (MRI/MRA) is necessary to determine&#x000a0;the&#x000a0;extent of brain infarcts and vascular abnormalities. An echocardiogram must be performed to estimate&#x000a0;pulmonary arterial pressures. Dental clearance and pulmonary function tests are also a part of pretransplant testing.</p>
        <p>Most importantly, HLA-typing&#x000a0;must be performed to&#x000a0;identify a suitable donor. The red cell phenotype of the recipient and donor is obtained. Screening for donor-directed antibodies is undertaken because of the risk of pure red cell aplasia after HSCT.<xref ref-type="bibr" rid="article-52226.r16">[16]</xref><xref ref-type="bibr" rid="article-52226.r17">[17]</xref>&#x000a0;Hydroxyurea must be&#x000a0;discontinued&#x000a0;before&#x000a0;HSCT, and exchange transfusion is often initiated to minimize the risk of complications. Patients and their families should be counseled about the risk of infertility; options for fertility preservation should be offered before&#x000a0;initiating the transplantation process.</p>
      </sec>
      <sec id="article-52226.s6" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>Bone marrow transplantation is more accurately described as hematopoietic stem cell transplantation (HSCT). HSCT is broadly&#x000a0;categorized into two types, autologous, where an individual receives their own stem cells, and allogeneic, where an individual receives stem cells from another individual, termed the donor. Autologous HSCT is typically not helpful in SCD unless the stem cells have been modified by genetic techniques to correct the underlying genetic mutation. Allogeneic HSCT is more widely used; the donor must be matched and can be a sibling or unrelated donor, although matched sibling donors are preferred. Matching refers to human leukocyte antigen (HLA); donors and recipients are considered fully matched if they have identical sequences at&#x000a0;8 out of 8 HLA loci.</p>
        <p>Hematopoietic stem cell transplantation techniques have been developed and refined continuously since the first transplant was&#x000a0;performed in 1984. The HSCT technique&#x000a0;requires a conditioning or preparative regimen&#x000a0;of chemotherapy to ablate the stem cells of the recipient. The aplastic marrow is repopulated by healthy donor stem cells. The preparative regimen of the first&#x000a0;HSCT in 1984 included cyclophosphamide at 120 mg/kg and fractionated total body irradiation.<xref ref-type="bibr" rid="article-52226.r18">[18]</xref> The patient then received GVHD prophylaxis consisting of a short course of methotrexate and methylprednisolone. Since then, significant strides have been made with conditioning regimens, including developing lower-intensity treatments&#x000a0;such as nonmyeloablative and reduced-intensity conditioning regimens that induce cytopenias to allow donor cell engraftment but do not completely ablate the marrow.<xref ref-type="bibr" rid="article-52226.r19">[19]</xref>&#x000a0;Administration of cyclophosphamide after HSCT is another advancement that has markedly improved outcomes in allogeneic HSCT, but its use is typically limited to patients receiving haploidentical stem cells.<xref ref-type="bibr" rid="article-52226.r20">[20]</xref><xref ref-type="bibr" rid="article-52226.r21">[21]</xref></p>
        <p>Myeloablative regimens that combine cytotoxic chemotherapy and total body irradiation are typically used for HSCT in SCD. Examples of commonly employed regimens include busulfan plus cyclophosphamide&#x000a0;or busulfan plus fludarabine. One study described the combination of thiotepa, fludarabine, and treosulfan with excellent long-term results.<xref ref-type="bibr" rid="article-52226.r22">[22]</xref>&#x000a0;Once the conditioning regimen has been administered and the donor stem cells have been transfused, the patient is assessed for engraftment and donor chimerism, the proportion of hematopoietic cells derived from the donor. Donor chimerism&#x000a0;of &#x02265;20% is needed to assure the production of enough non-HbS hemoglobin that sickling will not occur, thus&#x000a0;producing&#x000a0;a clinical cure.<xref ref-type="bibr" rid="article-52226.r12">[12]</xref>&#x000a0;Care should be taken to avoid using granulocyte-colony stimulating factor after transplantation because of reports of fatal cases of sickle cell crises with this agent.<xref ref-type="bibr" rid="article-52226.r23">[23]</xref>&#x000a0;Recipients should receive&#x000a0;immunizations&#x000a0;after the transplant procedure per standard protocols for bone marrow transplantation. Prophylaxis against GVHD and opportunistic infections must be initiated similarly to other indications for HSCT.</p>
      </sec>
      <sec id="article-52226.s7" sec-type="Complications">
        <title>Complications</title>
        <p>Since the first&#x000a0;HSCT was performed in 1984, over 1200 cases have been described. Complications arising from transplantation can be grouped into medical complications from the conditioning regimen, the transplantation itself, the immunosuppressive therapy used after transplantation, or financial toxicity.</p>
        <p>Conditioning regimens are highly toxic and can be associated with short-term organ injury and long-term effects such as infertility and secondary malignancies.<xref ref-type="bibr" rid="article-52226.r24">[24]</xref><xref ref-type="bibr" rid="article-52226.r25">[25]</xref> Transplantation itself is associated with a high risk of morbidity and mortality, especially if there is a mismatch. HSCT is safest when a matched donor is available, but unfortunately, only a few transplant candidates have such donors. Even with a suitable donor, there is still a&#x000a0;9% risk of graft rejection and a 15% risk of chronic GVHD.<xref ref-type="bibr" rid="article-52226.r15">[15]</xref> The immunosuppressive therapy needed to suppress GVHD predisposes patients to opportunistic infections, which can occasionally be fatal. Nonhealing leg wounds in some patients compound the risk of infection, although this is not necessarily a barrier to HSCT.<xref ref-type="bibr" rid="article-52226.r26">[26]</xref> Finally, significant financial costs associated with&#x000a0;HSCT&#x000a0;can be burdensome, especially for patients&#x000a0;from&#x000a0;socioeconomically disadvantaged backgrounds.<xref ref-type="bibr" rid="article-52226.r27">[27]</xref></p>
        <p>The potential for one or more of these complications should be carefully considered when evaluating an individual with&#x000a0;SCD for HSCT. The patient and their&#x000a0;caregivers should be educated about these complications to make an informed decision. Moreover,&#x000a0;with appropriate counseling, the patient and their&#x000a0;caregivers are better prepared to deal with complications, ultimately improving outcomes. Mitigation strategies for these complications vary depending on the circumstances.</p>
        <p>Complications in the immediate period during and after transplantation, such as infections, organ injury from the conditioning regimen, and acute&#x000a0;GVHD, are usually managed by the transplant team with protocols similar to those used in patients receiving HSCT for other indications. However, more long-term complications, such as late secondary malignancies, are often managed with close screening, the burden of which is shared between the transplant team and other health professionals. Infertility should be managed preemptively with counseling regarding fertility preservation options before the transplantation procedure.</p>
      </sec>
      <sec id="article-52226.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>HSCT currently represents the only curative option for&#x000a0;SCD, which is otherwise a chronic and incurable condition with complications that affect multiple organs leading to reduced quality of life and shortened survival. HSCT is associated with excellent overall and event-free survival and improvement in vaso-occlusive phenomena.<xref ref-type="bibr" rid="article-52226.r28">[28]</xref> However, HSCT does carry a risk of significant toxicity, which limits its use in clinical practice to young patients with good organ function but at high risk of complications. This represents only a small portion of the population living with SCD.</p>
        <p>Allogeneic HSCT also requires the identification of a suitable donor, typically a matched sibling. Thus allogeneic HSCT is not an option for&#x000a0;most patients with SCD, despite the advances that have been made in this field. Autologous stem cell transplantation with genetically modified stem cells is&#x000a0;expected to overcome some of these limitations. Although not commercially available, several gene therapy&#x000a0;treatments are awaiting FDA approval.<xref ref-type="bibr" rid="article-52226.r7">[7]</xref></p>
      </sec>
      <sec id="article-52226.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sickle cell disease is a complex disorder affecting multiple organ systems that requires care coordination&#x000a0;among various teams of healthcare&#x000a0;professionals to ensure optimal outcomes.&#x000a0;HSCT&#x000a0;is a highly specialized field requiring a team of trained physicians, nurses, pharmacists, stem cell technicians, and other services such as infectious disease and intensive care teams. Close coordination&#x000a0;among these teams is critical for successful outcomes; HSCT procedures are only performed at tertiary care centers with adequate experience and infrastructure.</p>
        <p>However, optimizing these outcomes requires extending this effort beyond the transplant center to pediatric and adult hematologists working in the community so that affected individuals are referred at the appropriate time for evaluation for HSCT. Creating&#x000a0;awareness of this therapeutic option among hematologists caring for individuals living with SCD is critical. Expanding access to HSCT and continuing research into improving the safety and efficacy of HSCT in patients with SCD represent the measures most likely to improve patient safety and outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-52226.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=52226&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=52226">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/52226/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=52226">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-52226.s11">
        <title>References</title>
        <ref id="article-52226.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavanagh</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Fasipe</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wun</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Sickle Cell Disease: A Review.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Jul</month>
            <day>05</day>
            <volume>328</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-68</page-range>
            <pub-id pub-id-type="pmid">35788790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zivot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Narla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blanc</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Erythropoiesis: insights into pathophysiology and treatments in 2017.</article-title>
            <source>Mol Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>23</day>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <pub-id pub-id-type="pmid">30134792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernaudin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Verlhac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peffault de Latour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Brousse</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Petras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Thuret</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Paillard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Galambrun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Divialle-Doumdo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pondarr&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guitton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Missud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Runel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jubert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elana</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ducros-Miralles</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Drain</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ta&#x000ef;eb</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Arnaud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamdem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malric</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elmaleh-Berg&#x000e8;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vasile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leveill&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soci&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chevret</surname>
                <given-names>S</given-names>
              </name>
              <collab>DREPAGREFFE Trial Investigators</collab>
            </person-group>
            <article-title>Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in Children With Sickle Cell Anemia.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Jan</month>
            <day>22</day>
            <volume>321</volume>
            <issue>3</issue>
            <fpage>266</fpage>
            <page-range>266-276</page-range>
            <pub-id pub-id-type="pmid">30667500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urbinati</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wherley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geiger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romero</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Marchioni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nowicki</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grassman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Viswanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hollis</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Preclinical studies for a phase 1 clinical trial of autologous hematopoietic stem cell gene therapy for sickle cell disease.</article-title>
            <source>Cytotherapy</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>1096</fpage>
            <page-range>1096-1112</page-range>
            <pub-id pub-id-type="pmid">28733131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uchida</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bonifacino</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Krouse</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Donahue</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients.</article-title>
            <source>Hum Gene Ther Clin Dev</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>136</fpage>
            <page-range>136-144</page-range>
            <pub-id pub-id-type="pmid">28447889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kamani</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campigotto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dahdoul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>De Castro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakshi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haight</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hassell</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Loving</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Spearman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wiedl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study.</article-title>
            <source>Am J Hematol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>446</fpage>
            <page-range>446-454</page-range>
            <pub-id pub-id-type="pmid">30637784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kingwell</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>First CRISPR therapy seeks landmark approval.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2023</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>339</fpage>
            <page-range>339-341</page-range>
            <pub-id pub-id-type="pmid">37012339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alonso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Vicent</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belendez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Badell</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sastre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Villa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berm&#x000fa;dez-Cort&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hladun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az de Heredia</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic stem cell transplantation in pediatric patients with thalassemia and sickle cell disease: An experience of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON).</article-title>
            <source>Med Clin (Barc)</source>
            <year>2019</year>
            <month>Feb</month>
            <day>15</day>
            <volume>152</volume>
            <issue>4</issue>
            <fpage>135</fpage>
            <page-range>135-140</page-range>
            <pub-id pub-id-type="pmid">30001893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brennan-Cook</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bonnabeau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aponte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Augustin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Barriers to Care for Persons With Sickle Cell Disease: The Case Manager's Opportunity to Improve Patient Outcomes.</article-title>
            <source>Prof Case Manag</source>
            <year>2018</year>
            <season>Jul/Aug</season>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>213</fpage>
            <page-range>213-219</page-range>
            <pub-id pub-id-type="pmid">29846351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walters</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Update of hematopoietic cell transplantation for sickle cell disease.</article-title>
            <source>Curr Opin Hematol</source>
            <year>2015</year>
            <month>May</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-33</page-range>
            <pub-id pub-id-type="pmid">25767957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yawn</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Afenyi-Annan</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Ballas</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hassell</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lanzkron</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lottenberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fulwood</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>John-Sowah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Sep</month>
            <day>10</day>
            <volume>312</volume>
            <issue>10</issue>
            <fpage>1033</fpage>
            <page-range>1033-48</page-range>
            <pub-id pub-id-type="pmid">25203083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guilcher</surname>
                <given-names>GMT</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Saraf</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rondelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.</article-title>
            <source>Semin Hematol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>87</fpage>
            <page-range>87-93</page-range>
            <pub-id pub-id-type="pmid">29958564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hulbert</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Shenoy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>e27263</fpage>
            <pub-id pub-id-type="pmid">29797658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Brazauskas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aplenc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atsuta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dalal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Khera</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bonfim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Majhail</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Freytes</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Savani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Kamble</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beattie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dandoy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Munker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bitan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abdel-Azim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aljurf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eckrich</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gergis</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rangarajan</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lipscomb</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saber</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Satwani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.</article-title>
            <source>Haematologica</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>11</issue>
            <fpage>1823</fpage>
            <page-range>1823-1832</page-range>
            <pub-id pub-id-type="pmid">28818869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gluckman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cappelli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bernaudin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Labopin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carreras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pinto Sim&#x000f5;es</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ferster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de la Fuente</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Zecca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yanik</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kurtzberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dhedin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuentz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Apperley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lutz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Vannier</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ayas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavazzana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matthes-Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Elayoubi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kenzey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bader</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eapen</surname>
                <given-names>M</given-names>
              </name>
              <collab>Eurocord, the Pediatric Working Party of the European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research</collab>
            </person-group>
            <article-title>Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Mar</month>
            <day>16</day>
            <volume>129</volume>
            <issue>11</issue>
            <fpage>1548</fpage>
            <page-range>1548-1556</page-range>
            <pub-id pub-id-type="pmid">27965196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Piel</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Gaston</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ohene-Frempong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Panepinto</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Weatherall</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Vichinsky</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell disease.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>4</volume>
            <fpage>18010</fpage>
            <pub-id pub-id-type="pmid">29542687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frangoul</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Isbell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Domm</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy&#x000a0;tbi and post transplant cyclophosphamide.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2018</year>
            <month>May</month>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>647</fpage>
            <page-range>647-650</page-range>
            <pub-id pub-id-type="pmid">29339800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzhugh</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>1171</fpage>
            <page-range>1171-85</page-range>
            <pub-id pub-id-type="pmid">25459186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernaudin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pondarr&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Galambrun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thuret</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Allogeneic/Matched Related Transplantation for &#x003b2;-Thalassemia and Sickle Cell Anemia.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2017</year>
            <volume>1013</volume>
            <fpage>89</fpage>
            <page-range>89-122</page-range>
            <pub-id pub-id-type="pmid">29127678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rangarajan</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Abu-Arja</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guilcher</surname>
                <given-names>GMT</given-names>
              </name>
              <name>
                <surname>Soni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>413</fpage>
            <page-range>413-417</page-range>
            <pub-id pub-id-type="pmid">29061531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzhugh</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coles</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Roskom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jeffries</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gamper</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luznik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.</article-title>
            <source>Blood Adv</source>
            <year>2017</year>
            <month>Apr</month>
            <day>25</day>
            <volume>1</volume>
            <issue>11</issue>
            <fpage>652</fpage>
            <page-range>652-661</page-range>
            <pub-id pub-id-type="pmid">29296707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strocchio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zecca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Comoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mina</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Giorgiani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giraldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vinti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Regazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.</article-title>
            <source>Br J Haematol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>169</volume>
            <issue>5</issue>
            <fpage>726</fpage>
            <page-range>726-36</page-range>
            <pub-id pub-id-type="pmid">25818248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adler</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Salzman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Carabasi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Vaughan</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Prchal</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Fatal sickle cell crisis after granulocyte colony-stimulating factor administration.</article-title>
            <source>Blood</source>
            <year>2001</year>
            <month>May</month>
            <day>15</day>
            <volume>97</volume>
            <issue>10</issue>
            <fpage>3313</fpage>
            <page-range>3313-4</page-range>
            <pub-id pub-id-type="pmid">11368061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pecker</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>21</day>
            <volume>11</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">35566443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eapen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brazauskas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>St Martin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Antin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bona</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaudhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coleman-Cowger</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>DiFronzo</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Esrick</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fitzhugh</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Kanter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kohn</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Pulsipher</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Talib</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Wun</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.</article-title>
            <source>J Clin Oncol</source>
            <year>2023</year>
            <month>Apr</month>
            <day>20</day>
            <volume>41</volume>
            <issue>12</issue>
            <fpage>2227</fpage>
            <page-range>2227-2237</page-range>
            <pub-id pub-id-type="pmid">36623245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connor</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Minniti</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Sickle Cell Anemia and Comorbid Leg Ulcer Treated With Curative Peripheral Blood Stem Cell Transplantation.</article-title>
            <source>Int J Low Extrem Wounds</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-59</page-range>
            <pub-id pub-id-type="pmid">28682672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Gaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease.</article-title>
            <source>Transplant Cell Ther</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>284</fpage>
            <page-range>284-285</page-range>
            <pub-id pub-id-type="pmid">33836866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-52226.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walters</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adamkiewicz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barkovich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bernaudin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Bunin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dickerhoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Haut</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Horan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Kamani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ohene-Frempong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patience</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Redding-Lallinger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>KM</given-names>
              </name>
              <collab>Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease</collab>
            </person-group>
            <article-title>Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-72</page-range>
            <pub-id pub-id-type="pmid">19822218</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
